J. Goldman & CO LP Oncternal Therapeutics, Inc. Transaction History

J. Goldman & CO LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$3.37 - $4.76 $416,565 - $588,383	-123,610 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$4.75 - $9.39 $273,348 - $540,366	57,547 Added 87.11%	123,610 $587,000
Q1 2021 May 17, 2021	SELL	$4.59 - $9.04 $279,916 - $551,295	-60,984 Reduced 48.0%	66,063 $550,000
Q4 2020 Feb 16, 2021	BUY	$1.51 - $6.3 $191,840 - $800,396	127,047 New	127,047 $623,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.